CORALreef Extension: Enlicitide Sustains LDL-C Reductions in Interim Analysis of OLE
Merck's enlicitide sustained LDL-C reductions in a 3-year extension study, with 87% of trial participants opting to continue. Interim results showed mean LDL-C reduction of -57.5% at week 8, with low discontinuation rates due to adverse events. The study aims to evaluate long-term safety and efficacy of the drug, which was approved in July 2026.
How this was made

The 30-second read
Why it matters
The interim results reinforce the drug's market potential and could drive Merck's stock higher, especially as cardiovascular drugs remain a high‑growth area.
Market read
First public release of robust extension data for a newly approved PCSK9 inhibitor, likely to influence Merck's valuation and the lipid‑lowering drug sector.
What to watch
Potential competition from upcoming RNA‑based lipid therapies could temper enthusiasm.
Background
Enlicitide (MK‑0616) received FDA approval in July 2026; the CORALreef Extension study provides longer‑term safety and efficacy data.
Ticker impact
Interim open‑label extension data for enlicitide (PCSK9 inhibitor) showing ~57% LDL‑C reduction and low adverse events were disclosed for the first time.
likely upward pressure as the market prices in the strong lipid‑lowering results.
First public disclosure of robust Phase‑3 extension outcomes for a newly approved therapy; investors typically reward such data.
Market effects
Strengthens the broader PCSK9 inhibitor and lipid‑lowering drug sector, potentially benefiting peers.
U.S. biotech and pharma markets may see modest gains from the data.
Highlights continued innovation in cardiovascular therapeutics, relevant to global investors.
Counterpoint
Skeptics may question long‑term durability beyond the interim 8‑week data and await full 3‑year results.
Key entities
- CompanyMerck Sharp & Dohme LLC
Pharmaceutical company that developed enlicitide.
- ExecutiveChristie Ballantyne, MD
Chief of cardiology and cardiovascular research at Baylor College of Medicine, presenting the data.



